Price of ZYNTEGLO reflects potentially curative clinical benefit through achievement of durable transfusion independence and normal or near normal total hemoglobin levels
Innovative outcomes-based contract offering includes single upfront payment and up to 80% risk-sharing
ZYNTEGLO will be available through a network of Qualified Treatment Centers with experience delivering novel cell and gene therapies
“my bluebird support” patient services program will provide comprehensive, personalized support for patients and their families
